Incyte will acquire Vega Therapeutics in a deal that could reach about $2.0 billion, with the acquisition aimed at adding a late-stage bleeding disorder medicine to its late-phase portfolio. The target is designed to control bleeding, reinforcing Incyte’s strategy to replace future revenue streams as existing assets face competitive and patent pressure. The transaction adds to the consolidation wave across hematology, where late-stage candidates and differentiated mechanisms can quickly change the risk profile of large biopharma portfolios. Incyte’s announcement also signals confidence in clinical readiness and regulatory timelines for Vega’s program. Terms were reported as potentially scaling up to roughly $2 billion, with the structure positioned as a major step in extending Incyte’s late-phase constellation.